The adoption rate for Accuray’s Xsight Lung Tracking System, a system designed for the noninvasive treatment of lung tumors, is exceeding 97 percent, the company announced. Xsight Lung is designed for use with the CyberKnife Robotic Radiosurgery System.
"The CyberKnife System with Xsight Lung Tracking allows us to break down the barriers to lung cancer treatment. We are now able to give new hope to patients — such as the elderly and those considered medically or surgically inoperable — who previously would have had no other option," said James Schwade, M.D., executive director of the CyberKnife Centers of Miami and Palm Beach.
According to the company, by working seamlessly with Accuray's CyberKnife System and Synchrony Respiratory Tracking System, Xsight Lung Tracking is the only system that uses the body's soft tissue to directly track targets with radiosurgical accuracy. It delivers highly specialized soft tissue tracking by using the actual image intensity of the lung tumor to target the beam, therefore eliminating the need in some cases for implanted fiducial markers.
An additional tool in the treatment of lung cancer is Accuray’s Monte Carlo dose calculation methodology, currently pending FDA 510(k) clearance. Designed to be fast and accurate, the Monte Carlo dose calculation reportedly enables clinicians to more precisely determine, in a matter of minutes, the intensity of radiation to be delivered in areas where tissue densities vary. This is particularly critical with lung cancer, since healthy tissue surrounding tumors is made up of air cavities, which are less dense than the solid tumors.
“Incorporating Monte Carlo dose calculation capabilities into the CyberKnife System will enable clinicians to quickly and precisely plan treatment and accurately determine the resulting radiation delivered to tumors,” said Charlie Ma, Ph.D., director of radiation physics at Fox Chase Cancer Center in Philadelphia.